Date: 2015-10-05
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in the International Journal of Obesity
Company: Atara Biotherapeutics (USA - CA)
Product: PINTA 745
Action
mechanism: peptibody. PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth. Through its biologic activity in blocking myostatin activity and in mitigating inflammatory mediators, PINTA 745 may have the potential to decrease the manifestations of protein-energy wasting, reduce the rates of serious complications, and improve functional status.
Disease: obesity, type II diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On October 5, 2015, Atara Biotherapeutics, a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, announced the publication of preclinical data that provide insight into the pharmacology of its clinical stage anti-myostatin peptibody, PINTA 745. In the International Journal of Obesity, investigators from Baylor College of Medicine utilized a high fat diet (HFD)-fed mouse model of obesity and type II diabetes to evaluate the effects of myostatin inhibition using PINTA 745 (http://www.nature.com/ijo/journal/vaop/naam/index.html#05102015).
